Catherine Wood's BEAM Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 12.47 M shares of Beam Therapeutics Inc. (BEAM) worth $345.59 M, representing 2.29% of the portfolio. First purchased in 2020-Q4, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in BEAM, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2021, adding 3.65 M shares. Largest reduction occurred in Q1 2024, reducing 1.21 M shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's Beam Therapeutics (BEAM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Beam Therapeutics (BEAM) Trades by Catherine Wood
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +1.43 M | Add 12.94% | 12.47 M | $27.72 |
| Q3 2025 | +2.19 M | Add 24.76% | 11.04 M | $24.27 |
| Q2 2025 | +367,752 | Add 4.34% | 8.85 M | $17.01 |
| Q1 2025 | +1.41 M | Add 19.98% | 8.48 M | $19.53 |
| Q4 2024 | +536,930 | Add 8.22% | 7.07 M | $24.80 |
| Q3 2024 | -1.1 M | Reduce 14.36% | 6.53 M | $24.50 |
| Q2 2024 | -556,035 | Reduce 6.80% | 7.63 M | $23.43 |
| Q1 2024 | -1.21 M | Reduce 12.90% | 8.18 M | $33.04 |
| Q4 2023 | +609,998 | Add 6.94% | 9.39 M | $27.22 |
| Q3 2023 | +401,296 | Add 4.79% | 8.78 M | $24.05 |
| Q2 2023 | -190,834 | Reduce 2.23% | 8.38 M | $31.93 |
| Q1 2023 | +360,298 | Add 4.39% | 8.57 M | $30.62 |
| Q4 2022 | -277,805 | Reduce 3.27% | 8.21 M | $39.11 |
| Q3 2022 | -301,128 | Reduce 3.42% | 8.49 M | $47.64 |
| Q2 2022 | +591,315 | Add 7.21% | 8.79 M | $35.18 |
| Q1 2022 | +217,348 | Add 2.72% | 8.2 M | $57.30 |
| Q4 2021 | +1.14 M | Add 16.69% | 7.98 M | $79.69 |
| Q3 2021 | +380,355 | Add 5.89% | 6.84 M | $87.01 |
| Q2 2021 | +1.68 M | Add 35.20% | 6.46 M | $128.71 |
| Q1 2021 | +3.65 M | Add 322.32% | 4.78 M | $80.04 |
| Q4 2020 | +1.13 M | New Buy | 1.13 M | $81.64 |
Catherine Wood's Beam Therapeutics Investment FAQs
Catherine Wood first purchased Beam Therapeutics Inc. (BEAM) in Q4 2020, acquiring 1,131,623 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held Beam Therapeutics Inc. (BEAM) for 21 quarters since Q4 2020.
Catherine Wood's largest addition to Beam Therapeutics Inc. (BEAM) was in Q1 2021, adding 4,779,104 shares worth $382.52 M.
According to the latest 13F filing for Q4 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 12,467,189 shares of Beam Therapeutics Inc. (BEAM), valued at approximately $345.59 M.
As of the Q4 2025 filing, Beam Therapeutics Inc. (BEAM) represents approximately 2.29% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.
Catherine Wood's peak holding in Beam Therapeutics Inc. (BEAM) was 12,467,189 shares, as reported at the end of Q4 2025.